nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—Central Nervous System Stimulation—Methamphetamine—obesity	0.257	1	CiPCiCtD
Lisdexamfetamine—Methamphetamine—obesity	0.195	1	CrCtD
Lisdexamfetamine—attention deficit hyperactivity disorder—Methamphetamine—obesity	0.0756	0.5	CpDpCtD
Lisdexamfetamine—attention deficit hyperactivity disorder—Bupropion—obesity	0.0756	0.5	CpDpCtD
Lisdexamfetamine—SLC18A2—Benzphetamine—obesity	0.0225	0.124	CbGbCtD
Lisdexamfetamine—SLC18A2—Methamphetamine—obesity	0.018	0.0991	CbGbCtD
Lisdexamfetamine—SLC6A3—Diethylpropion—obesity	0.0148	0.0814	CbGbCtD
Lisdexamfetamine—SLC6A3—Sibutramine—obesity	0.0112	0.0617	CbGbCtD
Lisdexamfetamine—SLC6A3—Phendimetrazine—obesity	0.0112	0.0617	CbGbCtD
Lisdexamfetamine—SLC6A2—Diethylpropion—obesity	0.0108	0.0596	CbGbCtD
Lisdexamfetamine—ADRA1B—Phendimetrazine—obesity	0.00899	0.0495	CbGbCtD
Lisdexamfetamine—SLC6A3—Benzphetamine—obesity	0.00849	0.0468	CbGbCtD
Lisdexamfetamine—SLC6A3—Phentermine—obesity	0.00849	0.0468	CbGbCtD
Lisdexamfetamine—SLC6A2—Sibutramine—obesity	0.0082	0.0451	CbGbCtD
Lisdexamfetamine—SLC6A2—Phendimetrazine—obesity	0.0082	0.0451	CbGbCtD
Lisdexamfetamine—SLC6A3—Phenylpropanolamine—obesity	0.0081	0.0446	CbGbCtD
Lisdexamfetamine—Selegiline—Diethylpropion—obesity	0.00758	0.0482	CrCrCtD
Lisdexamfetamine—SLC6A3—Bupropion—obesity	0.00722	0.0398	CbGbCtD
Lisdexamfetamine—SLC6A3—Methamphetamine—obesity	0.00679	0.0374	CbGbCtD
Lisdexamfetamine—Lacosamide—Phentermine—obesity	0.00657	0.0418	CrCrCtD
Lisdexamfetamine—Phenelzine—Phenylpropanolamine—obesity	0.00646	0.0411	CrCrCtD
Lisdexamfetamine—Selegiline—Phentermine—obesity	0.00626	0.0398	CrCrCtD
Lisdexamfetamine—SLC6A2—Phentermine—obesity	0.00622	0.0342	CbGbCtD
Lisdexamfetamine—SLC6A2—Benzphetamine—obesity	0.00622	0.0342	CbGbCtD
Lisdexamfetamine—Fenproporex—Phentermine—obesity	0.00598	0.038	CrCrCtD
Lisdexamfetamine—SLC6A2—Phenylpropanolamine—obesity	0.00593	0.0326	CbGbCtD
Lisdexamfetamine—Aspartame—Methamphetamine—obesity	0.00585	0.0372	CrCrCtD
Lisdexamfetamine—Lacosamide—Methamphetamine—obesity	0.00585	0.0372	CrCrCtD
Lisdexamfetamine—Selegiline—Methamphetamine—obesity	0.00558	0.0355	CrCrCtD
Lisdexamfetamine—Phenelzine—Phentermine—obesity	0.00549	0.0349	CrCrCtD
Lisdexamfetamine—Fenproporex—Methamphetamine—obesity	0.00533	0.0339	CrCrCtD
Lisdexamfetamine—SLC6A2—Bupropion—obesity	0.00529	0.0291	CbGbCtD
Lisdexamfetamine—Amphetamine—Diethylpropion—obesity	0.00524	0.0333	CrCrCtD
Lisdexamfetamine—Dextroamphetamine—Diethylpropion—obesity	0.00524	0.0333	CrCrCtD
Lisdexamfetamine—Methamphetamine—Diethylpropion—obesity	0.00509	0.0323	CrCrCtD
Lisdexamfetamine—Amphetamine—Phenylpropanolamine—obesity	0.00508	0.0323	CrCrCtD
Lisdexamfetamine—Dextroamphetamine—Phenylpropanolamine—obesity	0.00508	0.0323	CrCrCtD
Lisdexamfetamine—SLC6A2—Methamphetamine—obesity	0.00497	0.0274	CbGbCtD
Lisdexamfetamine—Methamphetamine—Phenylpropanolamine—obesity	0.00494	0.0314	CrCrCtD
Lisdexamfetamine—Phenelzine—Methamphetamine—obesity	0.0049	0.0311	CrCrCtD
Lisdexamfetamine—Phenacemide—Phentermine—obesity	0.00445	0.0283	CrCrCtD
Lisdexamfetamine—Selegiline—Benzphetamine—obesity	0.00442	0.0281	CrCrCtD
Lisdexamfetamine—Amphetamine—Phentermine—obesity	0.00432	0.0275	CrCrCtD
Lisdexamfetamine—Dextroamphetamine—Phentermine—obesity	0.00432	0.0275	CrCrCtD
Lisdexamfetamine—Fenproporex—Benzphetamine—obesity	0.00422	0.0269	CrCrCtD
Lisdexamfetamine—Methamphetamine—Phentermine—obesity	0.0042	0.0267	CrCrCtD
Lisdexamfetamine—L-Phenylalanine—Diethylpropion—obesity	0.00398	0.0253	CrCrCtD
Lisdexamfetamine—Phenacemide—Methamphetamine—obesity	0.00397	0.0252	CrCrCtD
Lisdexamfetamine—L-Phenylalanine—Phenylpropanolamine—obesity	0.00387	0.0246	CrCrCtD
Lisdexamfetamine—Amphetamine—Methamphetamine—obesity	0.00385	0.0245	CrCrCtD
Lisdexamfetamine—Dextroamphetamine—Methamphetamine—obesity	0.00385	0.0245	CrCrCtD
Lisdexamfetamine—L-Phenylalanine—Phentermine—obesity	0.00329	0.0209	CrCrCtD
Lisdexamfetamine—Dextroamphetamine—Benzphetamine—obesity	0.00305	0.0194	CrCrCtD
Lisdexamfetamine—Amphetamine—Benzphetamine—obesity	0.00305	0.0194	CrCrCtD
Lisdexamfetamine—Methamphetamine—Benzphetamine—obesity	0.00297	0.0189	CrCrCtD
Lisdexamfetamine—L-Phenylalanine—Methamphetamine—obesity	0.00293	0.0186	CrCrCtD
Lisdexamfetamine—SLC6A2—sympathetic nervous system—obesity	0.00081	0.291	CbGeAlD
Lisdexamfetamine—SLC6A2—autonomic nervous system—obesity	0.000544	0.196	CbGeAlD
Lisdexamfetamine—SLC6A3—hindbrain—obesity	0.000284	0.102	CbGeAlD
Lisdexamfetamine—Phenelzine—GPT—obesity	0.000183	0.184	CrCbGaD
Lisdexamfetamine—SLC6A3—respiratory system—obesity	0.000174	0.0625	CbGeAlD
Lisdexamfetamine—SLC18A2—adipose tissue—obesity	0.000155	0.0558	CbGeAlD
Lisdexamfetamine—Lacosamide—CA3—obesity	0.000153	0.154	CrCbGaD
Lisdexamfetamine—Amphetamine—CARTPT—obesity	0.000147	0.148	CrCbGaD
Lisdexamfetamine—SLC18A2—digestive system—obesity	0.000146	0.0525	CbGeAlD
Lisdexamfetamine—SLC6A2—respiratory system—obesity	0.00014	0.0504	CbGeAlD
Lisdexamfetamine—SLC18A2—adrenal gland—obesity	0.000139	0.05	CbGeAlD
Lisdexamfetamine—SLC18A2—endocrine gland—obesity	0.000121	0.0434	CbGeAlD
Lisdexamfetamine—Aspartame—TRPV1—obesity	0.00012	0.121	CrCbGaD
Lisdexamfetamine—Phenelzine—AOC3—obesity	0.000118	0.119	CrCbGaD
Lisdexamfetamine—SLC18A2—liver—obesity	0.000109	0.0391	CbGeAlD
Lisdexamfetamine—SLC6A2—adrenal gland—obesity	8.48e-05	0.0305	CbGeAlD
Lisdexamfetamine—Labetalol—ADRB3—obesity	7.81e-05	0.0788	CrCbGaD
Lisdexamfetamine—SLC6A2—endocrine gland—obesity	7.36e-05	0.0265	CbGeAlD
Lisdexamfetamine—Tachycardia—Diethylpropion—obesity	6.25e-05	0.00159	CcSEcCtD
Lisdexamfetamine—Libido decreased—Bupropion—obesity	6.23e-05	0.00158	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Diethylpropion—obesity	6.19e-05	0.00157	CcSEcCtD
Lisdexamfetamine—Headache—Benzphetamine—obesity	6.19e-05	0.00157	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Phendimetrazine—obesity	6.17e-05	0.00157	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Bupropion—obesity	6.1e-05	0.00155	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Cimetidine—obesity	6.1e-05	0.00155	CcSEcCtD
Lisdexamfetamine—Dizziness—Phendimetrazine—obesity	5.96e-05	0.00151	CcSEcCtD
Lisdexamfetamine—Tachycardia—Cimetidine—obesity	5.95e-05	0.00151	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Bupropion—obesity	5.9e-05	0.0015	CcSEcCtD
Lisdexamfetamine—Nausea—Benzphetamine—obesity	5.87e-05	0.00149	CcSEcCtD
Lisdexamfetamine—Urticaria—Phentermine—obesity	5.85e-05	0.00149	CcSEcCtD
Lisdexamfetamine—Insomnia—Diethylpropion—obesity	5.8e-05	0.00147	CcSEcCtD
Lisdexamfetamine—Diplopia—Bupropion—obesity	5.78e-05	0.00147	CcSEcCtD
Lisdexamfetamine—Aggression—Topiramate—obesity	5.77e-05	0.00147	CcSEcCtD
Lisdexamfetamine—Disturbance in sexual arousal—Bupropion—obesity	5.73e-05	0.00146	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Diethylpropion—obesity	5.71e-05	0.00145	CcSEcCtD
Lisdexamfetamine—Somnolence—Diethylpropion—obesity	5.7e-05	0.00145	CcSEcCtD
Lisdexamfetamine—Affect lability—Bupropion—obesity	5.69e-05	0.00144	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Phenylpropanolamine—obesity	5.67e-05	0.00144	CcSEcCtD
Lisdexamfetamine—Headache—Phendimetrazine—obesity	5.65e-05	0.00143	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Bupropion—obesity	5.64e-05	0.00143	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Diethylpropion—obesity	5.64e-05	0.00143	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Diethylpropion—obesity	5.53e-05	0.00141	CcSEcCtD
Lisdexamfetamine—Irritability—Bupropion—obesity	5.52e-05	0.0014	CcSEcCtD
Lisdexamfetamine—Constipation—Diethylpropion—obesity	5.48e-05	0.00139	CcSEcCtD
Lisdexamfetamine—Somnolence—Cimetidine—obesity	5.42e-05	0.00138	CcSEcCtD
Lisdexamfetamine—Dyskinesia—Topiramate—obesity	5.4e-05	0.00137	CcSEcCtD
Lisdexamfetamine—Nausea—Phendimetrazine—obesity	5.35e-05	0.00136	CcSEcCtD
Lisdexamfetamine—Asthenia—Phentermine—obesity	5.28e-05	0.00134	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Bupropion—obesity	5.28e-05	0.00134	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Sibutramine—obesity	5.28e-05	0.00134	CcSEcCtD
Lisdexamfetamine—Depression—Orlistat—obesity	5.26e-05	0.00134	CcSEcCtD
Lisdexamfetamine—Fatigue—Cimetidine—obesity	5.26e-05	0.00134	CcSEcCtD
Lisdexamfetamine—Constipation—Cimetidine—obesity	5.21e-05	0.00132	CcSEcCtD
Lisdexamfetamine—Weight increased—Sibutramine—obesity	5.21e-05	0.00132	CcSEcCtD
Lisdexamfetamine—Depression—Sibutramine—obesity	5.09e-05	0.00129	CcSEcCtD
Lisdexamfetamine—Urticaria—Diethylpropion—obesity	5.09e-05	0.00129	CcSEcCtD
Lisdexamfetamine—Dizziness—Phenylpropanolamine—obesity	5.09e-05	0.00129	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Phentermine—obesity	5.04e-05	0.00128	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Sibutramine—obesity	5.04e-05	0.00128	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Sibutramine—obesity	5.01e-05	0.00127	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Orlistat—obesity	4.99e-05	0.00127	CcSEcCtD
Lisdexamfetamine—Vomiting—Phenylpropanolamine—obesity	4.89e-05	0.00124	CcSEcCtD
Lisdexamfetamine—Dizziness—Phentermine—obesity	4.87e-05	0.00124	CcSEcCtD
Lisdexamfetamine—Rash—Phenylpropanolamine—obesity	4.85e-05	0.00123	CcSEcCtD
Lisdexamfetamine—Dermatitis—Phenylpropanolamine—obesity	4.85e-05	0.00123	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Cimetidine—obesity	4.82e-05	0.00122	CcSEcCtD
Lisdexamfetamine—Hepatitis—Orlistat—obesity	4.74e-05	0.0012	CcSEcCtD
Lisdexamfetamine—Vomiting—Phentermine—obesity	4.68e-05	0.00119	CcSEcCtD
Lisdexamfetamine—Rash—Phentermine—obesity	4.64e-05	0.00118	CcSEcCtD
Lisdexamfetamine—Dermatitis—Phentermine—obesity	4.64e-05	0.00118	CcSEcCtD
Lisdexamfetamine—Headache—Phentermine—obesity	4.61e-05	0.00117	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Bupropion—obesity	4.6e-05	0.00117	CcSEcCtD
Lisdexamfetamine—Nausea—Phenylpropanolamine—obesity	4.57e-05	0.00116	CcSEcCtD
Lisdexamfetamine—Weight increased—Bupropion—obesity	4.55e-05	0.00115	CcSEcCtD
Lisdexamfetamine—Weight decreased—Bupropion—obesity	4.52e-05	0.00115	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Cimetidine—obesity	4.49e-05	0.00114	CcSEcCtD
Lisdexamfetamine—Lisinopril—ACE—obesity	4.49e-05	0.0453	CrCbGaD
Lisdexamfetamine—Visual impairment—Sibutramine—obesity	4.42e-05	0.00112	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Bupropion—obesity	4.41e-05	0.00112	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Bupropion—obesity	4.39e-05	0.00112	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Diethylpropion—obesity	4.38e-05	0.00111	CcSEcCtD
Lisdexamfetamine—Nausea—Phentermine—obesity	4.38e-05	0.00111	CcSEcCtD
Lisdexamfetamine—Asthenia—Cimetidine—obesity	4.37e-05	0.00111	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Bupropion—obesity	4.36e-05	0.00111	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Topiramate—obesity	4.36e-05	0.00111	CcSEcCtD
Lisdexamfetamine—Eye disorder—Sibutramine—obesity	4.29e-05	0.00109	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Orlistat—obesity	4.28e-05	0.00109	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Orlistat—obesity	4.27e-05	0.00108	CcSEcCtD
Lisdexamfetamine—Dizziness—Diethylpropion—obesity	4.24e-05	0.00108	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Cimetidine—obesity	4.17e-05	0.00106	CcSEcCtD
Lisdexamfetamine—Mental disorder—Orlistat—obesity	4.15e-05	0.00105	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Sibutramine—obesity	4.14e-05	0.00105	CcSEcCtD
Lisdexamfetamine—Malnutrition—Orlistat—obesity	4.12e-05	0.00105	CcSEcCtD
Lisdexamfetamine—Vomiting—Diethylpropion—obesity	4.07e-05	0.00103	CcSEcCtD
Lisdexamfetamine—Rash—Diethylpropion—obesity	4.04e-05	0.00103	CcSEcCtD
Lisdexamfetamine—Dermatitis—Diethylpropion—obesity	4.04e-05	0.00103	CcSEcCtD
Lisdexamfetamine—Dizziness—Cimetidine—obesity	4.03e-05	0.00102	CcSEcCtD
Lisdexamfetamine—Headache—Diethylpropion—obesity	4.01e-05	0.00102	CcSEcCtD
Lisdexamfetamine—Hepatitis—Bupropion—obesity	4e-05	0.00102	CcSEcCtD
Lisdexamfetamine—Malnutrition—Sibutramine—obesity	3.99e-05	0.00101	CcSEcCtD
Lisdexamfetamine—Hallucination—Bupropion—obesity	3.98e-05	0.00101	CcSEcCtD
Lisdexamfetamine—Libido decreased—Topiramate—obesity	3.97e-05	0.00101	CcSEcCtD
Lisdexamfetamine—Vision blurred—Orlistat—obesity	3.89e-05	0.000987	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Topiramate—obesity	3.88e-05	0.000987	CcSEcCtD
Lisdexamfetamine—Nervousness—Sibutramine—obesity	3.88e-05	0.000985	CcSEcCtD
Lisdexamfetamine—Vomiting—Cimetidine—obesity	3.88e-05	0.000985	CcSEcCtD
Lisdexamfetamine—Visual impairment—Bupropion—obesity	3.85e-05	0.000979	CcSEcCtD
Lisdexamfetamine—Rash—Cimetidine—obesity	3.84e-05	0.000977	CcSEcCtD
Lisdexamfetamine—Dermatitis—Cimetidine—obesity	3.84e-05	0.000976	CcSEcCtD
Lisdexamfetamine—Headache—Cimetidine—obesity	3.82e-05	0.00097	CcSEcCtD
Lisdexamfetamine—Nausea—Diethylpropion—obesity	3.81e-05	0.000967	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Bupropion—obesity	3.78e-05	0.00096	CcSEcCtD
Lisdexamfetamine—Angioedema—Orlistat—obesity	3.77e-05	0.000957	CcSEcCtD
Lisdexamfetamine—Vision blurred—Sibutramine—obesity	3.76e-05	0.000956	CcSEcCtD
Lisdexamfetamine—Tremor—Sibutramine—obesity	3.74e-05	0.00095	CcSEcCtD
Lisdexamfetamine—Eye disorder—Bupropion—obesity	3.74e-05	0.000949	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Bupropion—obesity	3.71e-05	0.000942	CcSEcCtD
Lisdexamfetamine—Diplopia—Topiramate—obesity	3.68e-05	0.000935	CcSEcCtD
Lisdexamfetamine—Agitation—Sibutramine—obesity	3.67e-05	0.000932	CcSEcCtD
Lisdexamfetamine—Disturbance in sexual arousal—Topiramate—obesity	3.65e-05	0.000928	CcSEcCtD
Lisdexamfetamine—Angioedema—Sibutramine—obesity	3.65e-05	0.000927	CcSEcCtD
Lisdexamfetamine—Palpitations—Orlistat—obesity	3.64e-05	0.000926	CcSEcCtD
Lisdexamfetamine—Affect lability—Topiramate—obesity	3.62e-05	0.000921	CcSEcCtD
Lisdexamfetamine—Nausea—Cimetidine—obesity	3.62e-05	0.00092	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Bupropion—obesity	3.61e-05	0.000917	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Bupropion—obesity	3.6e-05	0.000915	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Topiramate—obesity	3.6e-05	0.000913	CcSEcCtD
Lisdexamfetamine—Convulsion—Orlistat—obesity	3.57e-05	0.000908	CcSEcCtD
Lisdexamfetamine—Labetalol—ADRB1—obesity	3.53e-05	0.0356	CrCbGaD
Lisdexamfetamine—Palpitations—Sibutramine—obesity	3.53e-05	0.000896	CcSEcCtD
Lisdexamfetamine—Irritability—Topiramate—obesity	3.51e-05	0.000893	CcSEcCtD
Lisdexamfetamine—Mental disorder—Bupropion—obesity	3.5e-05	0.00089	CcSEcCtD
Lisdexamfetamine—Anxiety—Orlistat—obesity	3.5e-05	0.000889	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	3.49e-05	0.000886	CcSEcCtD
Lisdexamfetamine—Malnutrition—Bupropion—obesity	3.48e-05	0.000884	CcSEcCtD
Lisdexamfetamine—Convulsion—Sibutramine—obesity	3.46e-05	0.000879	CcSEcCtD
Lisdexamfetamine—Hypertension—Sibutramine—obesity	3.45e-05	0.000875	CcSEcCtD
Lisdexamfetamine—Dry mouth—Orlistat—obesity	3.43e-05	0.000872	CcSEcCtD
Lisdexamfetamine—Anxiety—Sibutramine—obesity	3.39e-05	0.00086	CcSEcCtD
Lisdexamfetamine—Nervousness—Bupropion—obesity	3.38e-05	0.000859	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Orlistat—obesity	3.37e-05	0.000855	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Topiramate—obesity	3.36e-05	0.000854	CcSEcCtD
Lisdexamfetamine—Dry mouth—Sibutramine—obesity	3.32e-05	0.000844	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Topiramate—obesity	3.32e-05	0.000842	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Orlistat—obesity	3.3e-05	0.000839	CcSEcCtD
Lisdexamfetamine—Vision blurred—Bupropion—obesity	3.28e-05	0.000833	CcSEcCtD
Lisdexamfetamine—Skin disorder—Orlistat—obesity	3.27e-05	0.000831	CcSEcCtD
Lisdexamfetamine—Tremor—Bupropion—obesity	3.26e-05	0.000828	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Sibutramine—obesity	3.26e-05	0.000828	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Orlistat—obesity	3.25e-05	0.000827	CcSEcCtD
Lisdexamfetamine—Agitation—Bupropion—obesity	3.2e-05	0.000812	CcSEcCtD
Lisdexamfetamine—Angioedema—Bupropion—obesity	3.18e-05	0.000808	CcSEcCtD
Lisdexamfetamine—Tachycardia—Sibutramine—obesity	3.18e-05	0.000808	CcSEcCtD
Lisdexamfetamine—Skin disorder—Sibutramine—obesity	3.16e-05	0.000804	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Sibutramine—obesity	3.15e-05	0.0008	CcSEcCtD
Lisdexamfetamine—Anorexia—Sibutramine—obesity	3.11e-05	0.000789	CcSEcCtD
Lisdexamfetamine—Palpitations—Bupropion—obesity	3.08e-05	0.000781	CcSEcCtD
Lisdexamfetamine—Insomnia—Orlistat—obesity	3.04e-05	0.000773	CcSEcCtD
Lisdexamfetamine—Convulsion—Bupropion—obesity	3.02e-05	0.000766	CcSEcCtD
Lisdexamfetamine—Hypertension—Bupropion—obesity	3e-05	0.000763	CcSEcCtD
Lisdexamfetamine—Labetalol—ADRB2—obesity	2.97e-05	0.03	CrCbGaD
Lisdexamfetamine—Dyspepsia—Orlistat—obesity	2.96e-05	0.000753	CcSEcCtD
Lisdexamfetamine—Anxiety—Bupropion—obesity	2.95e-05	0.00075	CcSEcCtD
Lisdexamfetamine—Insomnia—Sibutramine—obesity	2.95e-05	0.000748	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	2.94e-05	0.000747	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Topiramate—obesity	2.93e-05	0.000744	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Orlistat—obesity	2.93e-05	0.000743	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Orlistat—obesity	2.91e-05	0.000738	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Sibutramine—obesity	2.9e-05	0.000738	CcSEcCtD
Lisdexamfetamine—Fatigue—Orlistat—obesity	2.9e-05	0.000737	CcSEcCtD
Lisdexamfetamine—Dry mouth—Bupropion—obesity	2.9e-05	0.000736	CcSEcCtD
Lisdexamfetamine—Somnolence—Sibutramine—obesity	2.9e-05	0.000736	CcSEcCtD
Lisdexamfetamine—Weight increased—Topiramate—obesity	2.9e-05	0.000736	CcSEcCtD
Lisdexamfetamine—Weight decreased—Topiramate—obesity	2.88e-05	0.000731	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Sibutramine—obesity	2.87e-05	0.000728	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Bupropion—obesity	2.84e-05	0.000721	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Sibutramine—obesity	2.83e-05	0.000719	CcSEcCtD
Lisdexamfetamine—Depression—Topiramate—obesity	2.83e-05	0.000719	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Topiramate—obesity	2.81e-05	0.000714	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Sibutramine—obesity	2.81e-05	0.000714	CcSEcCtD
Lisdexamfetamine—Constipation—Sibutramine—obesity	2.79e-05	0.000708	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Bupropion—obesity	2.79e-05	0.000708	CcSEcCtD
Lisdexamfetamine—Tachycardia—Bupropion—obesity	2.77e-05	0.000704	CcSEcCtD
Lisdexamfetamine—Skin disorder—Bupropion—obesity	2.76e-05	0.000701	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Bupropion—obesity	2.75e-05	0.000697	CcSEcCtD
Lisdexamfetamine—Anorexia—Bupropion—obesity	2.71e-05	0.000688	CcSEcCtD
Lisdexamfetamine—Urticaria—Orlistat—obesity	2.67e-05	0.000679	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Orlistat—obesity	2.66e-05	0.000676	CcSEcCtD
Lisdexamfetamine—Urticaria—Sibutramine—obesity	2.59e-05	0.000657	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Sibutramine—obesity	2.58e-05	0.000654	CcSEcCtD
Lisdexamfetamine—Insomnia—Bupropion—obesity	2.57e-05	0.000653	CcSEcCtD
Lisdexamfetamine—Hepatitis—Topiramate—obesity	2.55e-05	0.000647	CcSEcCtD
Lisdexamfetamine—Hallucination—Topiramate—obesity	2.53e-05	0.000644	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Bupropion—obesity	2.53e-05	0.000643	CcSEcCtD
Lisdexamfetamine—Somnolence—Bupropion—obesity	2.52e-05	0.000641	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Bupropion—obesity	2.5e-05	0.000635	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Orlistat—obesity	2.48e-05	0.00063	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Bupropion—obesity	2.47e-05	0.000627	CcSEcCtD
Lisdexamfetamine—Visual impairment—Topiramate—obesity	2.45e-05	0.000623	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Bupropion—obesity	2.45e-05	0.000623	CcSEcCtD
Lisdexamfetamine—Fatigue—Bupropion—obesity	2.45e-05	0.000622	CcSEcCtD
Lisdexamfetamine—Constipation—Bupropion—obesity	2.43e-05	0.000617	CcSEcCtD
Lisdexamfetamine—Asthenia—Orlistat—obesity	2.42e-05	0.000614	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Topiramate—obesity	2.41e-05	0.000612	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Sibutramine—obesity	2.4e-05	0.00061	CcSEcCtD
Lisdexamfetamine—Eye disorder—Topiramate—obesity	2.38e-05	0.000605	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Topiramate—obesity	2.36e-05	0.0006	CcSEcCtD
Lisdexamfetamine—Asthenia—Sibutramine—obesity	2.34e-05	0.000594	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Orlistat—obesity	2.3e-05	0.000585	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Topiramate—obesity	2.3e-05	0.000584	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Topiramate—obesity	2.3e-05	0.000583	CcSEcCtD
Lisdexamfetamine—Urticaria—Bupropion—obesity	2.26e-05	0.000573	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Bupropion—obesity	2.25e-05	0.00057	CcSEcCtD
Lisdexamfetamine—Mental disorder—Topiramate—obesity	2.23e-05	0.000567	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Sibutramine—obesity	2.23e-05	0.000566	CcSEcCtD
Lisdexamfetamine—Dizziness—Orlistat—obesity	2.23e-05	0.000565	CcSEcCtD
Lisdexamfetamine—Malnutrition—Topiramate—obesity	2.22e-05	0.000563	CcSEcCtD
Lisdexamfetamine—Dizziness—Sibutramine—obesity	2.15e-05	0.000547	CcSEcCtD
Lisdexamfetamine—Nervousness—Topiramate—obesity	2.15e-05	0.000547	CcSEcCtD
Lisdexamfetamine—Vomiting—Orlistat—obesity	2.14e-05	0.000544	CcSEcCtD
Lisdexamfetamine—Rash—Orlistat—obesity	2.12e-05	0.000539	CcSEcCtD
Lisdexamfetamine—Dermatitis—Orlistat—obesity	2.12e-05	0.000539	CcSEcCtD
Lisdexamfetamine—Headache—Orlistat—obesity	2.11e-05	0.000536	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Bupropion—obesity	2.09e-05	0.000532	CcSEcCtD
Lisdexamfetamine—Vision blurred—Topiramate—obesity	2.09e-05	0.000531	CcSEcCtD
Lisdexamfetamine—Tremor—Topiramate—obesity	2.08e-05	0.000528	CcSEcCtD
Lisdexamfetamine—Vomiting—Sibutramine—obesity	2.07e-05	0.000526	CcSEcCtD
Lisdexamfetamine—Rash—Sibutramine—obesity	2.05e-05	0.000522	CcSEcCtD
Lisdexamfetamine—Dermatitis—Sibutramine—obesity	2.05e-05	0.000521	CcSEcCtD
Lisdexamfetamine—Headache—Sibutramine—obesity	2.04e-05	0.000518	CcSEcCtD
Lisdexamfetamine—Asthenia—Bupropion—obesity	2.04e-05	0.000518	CcSEcCtD
Lisdexamfetamine—Agitation—Topiramate—obesity	2.04e-05	0.000518	CcSEcCtD
Lisdexamfetamine—Nausea—Orlistat—obesity	2e-05	0.000508	CcSEcCtD
Lisdexamfetamine—Palpitations—Topiramate—obesity	1.96e-05	0.000498	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Bupropion—obesity	1.94e-05	0.000494	CcSEcCtD
Lisdexamfetamine—Nausea—Sibutramine—obesity	1.94e-05	0.000492	CcSEcCtD
Lisdexamfetamine—Convulsion—Topiramate—obesity	1.92e-05	0.000488	CcSEcCtD
Lisdexamfetamine—Hypertension—Topiramate—obesity	1.91e-05	0.000486	CcSEcCtD
Lisdexamfetamine—Anxiety—Topiramate—obesity	1.88e-05	0.000478	CcSEcCtD
Lisdexamfetamine—Dizziness—Bupropion—obesity	1.88e-05	0.000477	CcSEcCtD
Lisdexamfetamine—Selegiline—CYP2E1—obesity	1.88e-05	0.0189	CrCbGaD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	1.87e-05	0.000476	CcSEcCtD
Lisdexamfetamine—Dry mouth—Topiramate—obesity	1.85e-05	0.000469	CcSEcCtD
Lisdexamfetamine—Vomiting—Bupropion—obesity	1.81e-05	0.000459	CcSEcCtD
Lisdexamfetamine—Rash—Bupropion—obesity	1.79e-05	0.000455	CcSEcCtD
Lisdexamfetamine—Dermatitis—Bupropion—obesity	1.79e-05	0.000454	CcSEcCtD
Lisdexamfetamine—Headache—Bupropion—obesity	1.78e-05	0.000452	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Topiramate—obesity	1.77e-05	0.000451	CcSEcCtD
Lisdexamfetamine—Tachycardia—Topiramate—obesity	1.77e-05	0.000449	CcSEcCtD
Lisdexamfetamine—Skin disorder—Topiramate—obesity	1.76e-05	0.000446	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Topiramate—obesity	1.75e-05	0.000444	CcSEcCtD
Lisdexamfetamine—Anorexia—Topiramate—obesity	1.72e-05	0.000438	CcSEcCtD
Lisdexamfetamine—Nausea—Bupropion—obesity	1.69e-05	0.000429	CcSEcCtD
Lisdexamfetamine—Phenelzine—CYP2E1—obesity	1.65e-05	0.0167	CrCbGaD
Lisdexamfetamine—Insomnia—Topiramate—obesity	1.64e-05	0.000416	CcSEcCtD
Lisdexamfetamine—Amphetamine—SLC6A4—obesity	1.63e-05	0.0165	CrCbGaD
Lisdexamfetamine—Amphetamine—DRD2—obesity	1.62e-05	0.0164	CrCbGaD
Lisdexamfetamine—Dyspnoea—Topiramate—obesity	1.61e-05	0.00041	CcSEcCtD
Lisdexamfetamine—Somnolence—Topiramate—obesity	1.61e-05	0.000409	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Topiramate—obesity	1.59e-05	0.000405	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Topiramate—obesity	1.57e-05	0.0004	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Topiramate—obesity	1.56e-05	0.000397	CcSEcCtD
Lisdexamfetamine—Fatigue—Topiramate—obesity	1.56e-05	0.000396	CcSEcCtD
Lisdexamfetamine—Constipation—Topiramate—obesity	1.55e-05	0.000393	CcSEcCtD
Lisdexamfetamine—Methamphetamine—SLC6A4—obesity	1.51e-05	0.0152	CrCbGaD
Lisdexamfetamine—Urticaria—Topiramate—obesity	1.44e-05	0.000365	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Topiramate—obesity	1.43e-05	0.000363	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Topiramate—obesity	1.33e-05	0.000339	CcSEcCtD
Lisdexamfetamine—Asthenia—Topiramate—obesity	1.3e-05	0.00033	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Topiramate—obesity	1.24e-05	0.000314	CcSEcCtD
Lisdexamfetamine—Dizziness—Topiramate—obesity	1.2e-05	0.000304	CcSEcCtD
Lisdexamfetamine—Vomiting—Topiramate—obesity	1.15e-05	0.000292	CcSEcCtD
Lisdexamfetamine—Rash—Topiramate—obesity	1.14e-05	0.00029	CcSEcCtD
Lisdexamfetamine—Dermatitis—Topiramate—obesity	1.14e-05	0.00029	CcSEcCtD
Lisdexamfetamine—Headache—Topiramate—obesity	1.13e-05	0.000288	CcSEcCtD
Lisdexamfetamine—Nausea—Topiramate—obesity	1.07e-05	0.000273	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—TFRC—obesity	6.45e-06	0.000433	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CNR1—obesity	6.39e-06	0.000428	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—PPARA—obesity	6.38e-06	0.000428	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PPY—obesity	6.36e-06	0.000426	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—PRKCB—obesity	6.33e-06	0.000424	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFB1—obesity	6.3e-06	0.000422	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—obesity	6.28e-06	0.000421	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GIP—obesity	6.25e-06	0.000419	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PRKCH—obesity	6.25e-06	0.000419	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—DRD2—obesity	6.24e-06	0.000418	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A4—obesity	6.19e-06	0.000415	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GCG—obesity	6.17e-06	0.000414	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT1—obesity	6.16e-06	0.000413	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—CYCS—obesity	6.11e-06	0.00041	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3R1—obesity	6.03e-06	0.000404	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—APOA1—obesity	5.99e-06	0.000401	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—NCOA1—obesity	5.91e-06	0.000396	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRB3—obesity	5.85e-06	0.000392	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—PLG—obesity	5.76e-06	0.000386	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—obesity	5.74e-06	0.000384	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—C3—obesity	5.73e-06	0.000384	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GAL—obesity	5.71e-06	0.000383	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—C5AR1—obesity	5.65e-06	0.000379	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ADRB2—obesity	5.59e-06	0.000375	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFB1—obesity	5.58e-06	0.000374	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—obesity	5.56e-06	0.000373	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NMB—obesity	5.53e-06	0.000371	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GHRH—obesity	5.53e-06	0.000371	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—obesity	5.5e-06	0.000368	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A4—obesity	5.49e-06	0.000368	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGT—obesity	5.44e-06	0.000365	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—CYCS—obesity	5.42e-06	0.000363	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3R1—obesity	5.4e-06	0.000362	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—GNB3—obesity	5.34e-06	0.000358	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GNB3—obesity	5.32e-06	0.000357	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—obesity	5.31e-06	0.000356	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRB3—obesity	5.31e-06	0.000356	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FFAR4—obesity	5.28e-06	0.000354	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—NCOA1—obesity	5.23e-06	0.000351	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—GNAS—obesity	5.2e-06	0.000348	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GAL—obesity	5.19e-06	0.000348	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GNAS—obesity	5.18e-06	0.000347	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCK—obesity	5.17e-06	0.000346	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—C5AR1—obesity	5.13e-06	0.000344	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—PLG—obesity	5.1e-06	0.000342	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—APOB—obesity	5.09e-06	0.000341	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GHSR—obesity	5.06e-06	0.000339	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BRS3—obesity	5.06e-06	0.000339	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MCHR1—obesity	5.06e-06	0.000339	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GLP1R—obesity	5.03e-06	0.000337	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—F2—obesity	5.03e-06	0.000337	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCL5—obesity	4.96e-06	0.000332	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HRH3—obesity	4.95e-06	0.000332	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCKAR—obesity	4.95e-06	0.000332	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ALB—obesity	4.74e-06	0.000318	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—GNB3—obesity	4.73e-06	0.000317	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—obesity	4.71e-06	0.000316	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRLHR—obesity	4.7e-06	0.000315	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GH1—obesity	4.7e-06	0.000315	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SH2B1—obesity	4.7e-06	0.000315	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCK—obesity	4.69e-06	0.000314	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—GNAS—obesity	4.61e-06	0.000309	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—obesity	4.58e-06	0.000307	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GLP1R—obesity	4.57e-06	0.000306	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—APOB—obesity	4.51e-06	0.000302	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HRH3—obesity	4.5e-06	0.000301	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCKAR—obesity	4.5e-06	0.000301	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—NPY—obesity	4.49e-06	0.000301	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL2—obesity	4.48e-06	0.0003	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IAPP—obesity	4.46e-06	0.000299	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APLN—obesity	4.42e-06	0.000296	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PYY—obesity	4.42e-06	0.000296	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR2A—obesity	4.37e-06	0.000293	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—C3—obesity	4.36e-06	0.000292	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PRKAR2B—obesity	4.33e-06	0.00029	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CRH—obesity	4.33e-06	0.00029	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR1B—obesity	4.33e-06	0.00029	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—PPARA—obesity	4.29e-06	0.000288	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PNLIP—obesity	4.19e-06	0.000281	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—AGT—obesity	4.14e-06	0.000278	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—NPS—obesity	4.1e-06	0.000275	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SDC3—obesity	4.09e-06	0.000274	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NPY—obesity	4.07e-06	0.000273	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IAPP—obesity	4.05e-06	0.000271	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—APOA1—obesity	4.03e-06	0.00027	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—DRD1—obesity	4.02e-06	0.00027	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR2C—obesity	4.02e-06	0.00027	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PMCH—obesity	4e-06	0.000268	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NPY5R—obesity	4e-06	0.000268	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NMU—obesity	4e-06	0.000268	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HCRT—obesity	4e-06	0.000268	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CRH—obesity	3.93e-06	0.000263	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR1B—obesity	3.93e-06	0.000263	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRB1—obesity	3.9e-06	0.000261	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MC3R—obesity	3.83e-06	0.000257	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NPY2R—obesity	3.83e-06	0.000257	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NPY1R—obesity	3.83e-06	0.000257	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MC4R—obesity	3.83e-06	0.000257	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—F2—obesity	3.83e-06	0.000257	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GHRL—obesity	3.82e-06	0.000256	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—PPARA—obesity	3.8e-06	0.000255	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—DRD4—obesity	3.78e-06	0.000254	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PPY—obesity	3.76e-06	0.000252	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NPS—obesity	3.73e-06	0.00025	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HDAC8—obesity	3.69e-06	0.000247	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKCH—obesity	3.69e-06	0.000247	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GIP—obesity	3.69e-06	0.000247	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—DRD1—obesity	3.65e-06	0.000245	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR2C—obesity	3.65e-06	0.000245	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CNR1—obesity	3.61e-06	0.000242	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—APOA1—obesity	3.57e-06	0.000239	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRB1—obesity	3.54e-06	0.000237	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—DRD2—obesity	3.52e-06	0.000236	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LEPR—obesity	3.51e-06	0.000235	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GCG—obesity	3.49e-06	0.000234	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—POMC—obesity	3.49e-06	0.000234	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GHRL—obesity	3.46e-06	0.000232	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—DRD4—obesity	3.44e-06	0.00023	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCL2—obesity	3.41e-06	0.000229	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—obesity	3.39e-06	0.000228	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CNR1—obesity	3.28e-06	0.00022	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—DRD2—obesity	3.2e-06	0.000215	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ALB—obesity	3.19e-06	0.000214	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GCG—obesity	3.17e-06	0.000212	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRB2—obesity	3.16e-06	0.000212	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRB3—obesity	3.14e-06	0.00021	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GAL—obesity	3.06e-06	0.000205	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—obesity	3.04e-06	0.000203	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—C5AR1—obesity	3.03e-06	0.000203	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GNB3—obesity	3.01e-06	0.000202	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GNAS—obesity	2.93e-06	0.000196	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRB2—obesity	2.87e-06	0.000192	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ALB—obesity	2.83e-06	0.000189	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCL5—obesity	2.8e-06	0.000188	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKG1—obesity	2.77e-06	0.000186	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCK—obesity	2.77e-06	0.000186	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GNB3—obesity	2.73e-06	0.000183	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RBP4—obesity	2.7e-06	0.000181	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GLP1R—obesity	2.7e-06	0.000181	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—obesity	2.69e-06	0.00018	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GNAS—obesity	2.66e-06	0.000178	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HRH3—obesity	2.66e-06	0.000178	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCKAR—obesity	2.66e-06	0.000178	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKAR2B—obesity	2.56e-06	0.000171	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCL5—obesity	2.54e-06	0.00017	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PRKCD—obesity	2.52e-06	0.000169	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NCF2—obesity	2.47e-06	0.000166	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR2A—obesity	2.47e-06	0.000165	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—C3—obesity	2.47e-06	0.000165	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NPY—obesity	2.41e-06	0.000161	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APOC3—obesity	2.39e-06	0.00016	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IAPP—obesity	2.39e-06	0.00016	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AGT—obesity	2.34e-06	0.000157	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CRH—obesity	2.32e-06	0.000156	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR1B—obesity	2.32e-06	0.000156	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SDC1—obesity	2.3e-06	0.000154	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PRKCD—obesity	2.29e-06	0.000154	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKR1C3—obesity	2.26e-06	0.000151	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR2A—obesity	2.24e-06	0.00015	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—C3—obesity	2.24e-06	0.00015	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NPS—obesity	2.2e-06	0.000148	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—F2—obesity	2.16e-06	0.000145	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PRKCB—obesity	2.16e-06	0.000145	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR2C—obesity	2.16e-06	0.000145	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DRD1—obesity	2.16e-06	0.000145	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AGT—obesity	2.13e-06	0.000143	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NTRK2—obesity	2.1e-06	0.000141	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRB1—obesity	2.09e-06	0.00014	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CG—obesity	2.07e-06	0.000139	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PARP1—obesity	2.05e-06	0.000137	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GHRL—obesity	2.05e-06	0.000137	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DRD4—obesity	2.03e-06	0.000136	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—POMC—obesity	1.97e-06	0.000132	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PRKCB—obesity	1.97e-06	0.000132	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—F2—obesity	1.97e-06	0.000132	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CNR1—obesity	1.94e-06	0.00013	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TCF7L2—obesity	1.9e-06	0.000128	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT2—obesity	1.9e-06	0.000127	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DRD2—obesity	1.89e-06	0.000127	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CG—obesity	1.88e-06	0.000126	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTPN1—obesity	1.87e-06	0.000125	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GCG—obesity	1.87e-06	0.000125	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CD—obesity	1.82e-06	0.000122	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—POMC—obesity	1.79e-06	0.00012	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRL—obesity	1.79e-06	0.00012	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STK11—obesity	1.76e-06	0.000118	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCL2—obesity	1.75e-06	0.000117	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PLG—obesity	1.74e-06	0.000117	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—RHOA—obesity	1.74e-06	0.000116	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT2—obesity	1.72e-06	0.000115	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3R1—obesity	1.72e-06	0.000115	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FOXO3—obesity	1.7e-06	0.000114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRB2—obesity	1.69e-06	0.000114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SOCS1—obesity	1.67e-06	0.000112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CD—obesity	1.65e-06	0.000111	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SOCS3—obesity	1.65e-06	0.00011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GNB3—obesity	1.61e-06	0.000108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—TYK2—obesity	1.59e-06	0.000107	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CB—obesity	1.59e-06	0.000106	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF2—obesity	1.58e-06	0.000106	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RHOA—obesity	1.58e-06	0.000106	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GNAS—obesity	1.57e-06	0.000105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3R1—obesity	1.56e-06	0.000105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APOB—obesity	1.54e-06	0.000103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCL5—obesity	1.5e-06	0.000101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LPL—obesity	1.47e-06	9.84e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FOXO1—obesity	1.46e-06	9.77e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RPS6KB1—obesity	1.46e-06	9.76e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CB—obesity	1.44e-06	9.66e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKCD—obesity	1.35e-06	9.07e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR2A—obesity	1.32e-06	8.88e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—C3—obesity	1.32e-06	8.86e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IRS2—obesity	1.26e-06	8.43e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AGT—obesity	1.26e-06	8.42e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APOE—obesity	1.23e-06	8.25e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LEP—obesity	1.23e-06	8.25e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CAV1—obesity	1.22e-06	8.18e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APOA1—obesity	1.22e-06	8.16e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ESR1—obesity	1.18e-06	7.88e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKCB—obesity	1.16e-06	7.78e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—F2—obesity	1.16e-06	7.78e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BAD—obesity	1.15e-06	7.69e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CG—obesity	1.11e-06	7.45e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IRS1—obesity	1.1e-06	7.36e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—POMC—obesity	1.06e-06	7.09e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—INS—obesity	1.05e-06	7.05e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCL2—obesity	1.03e-06	6.94e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1—obesity	1.02e-06	6.82e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT2—obesity	1.02e-06	6.81e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CD—obesity	9.77e-07	6.55e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CA—obesity	9.68e-07	6.48e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SERPINE1—obesity	9.66e-07	6.47e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TYK2—obesity	9.4e-07	6.3e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RHOA—obesity	9.32e-07	6.25e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3R1—obesity	9.22e-07	6.18e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOS3—obesity	9.22e-07	6.18e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CA—obesity	8.79e-07	5.89e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CB—obesity	8.51e-07	5.71e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MTOR—obesity	8.51e-07	5.71e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT1—obesity	7.9e-07	5.3e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6—obesity	7.78e-07	5.21e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP9—obesity	7.4e-07	4.96e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK8—obesity	7.2e-07	4.82e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT1—obesity	7.18e-07	4.81e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT3—obesity	6.58e-07	4.41e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYC—obesity	6.11e-07	4.1e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TGFB1—obesity	6.1e-07	4.09e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CA—obesity	5.19e-07	3.48e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6—obesity	4.6e-07	3.08e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT1—obesity	4.24e-07	2.84e-05	CbGpPWpGaD
